Effect of oral oleoyl-estrone treatment on plasma lipoproteins and tissue lipase activities of Zucker lean and obese female rats.
OBJECTIVE
To study the effect of oral oleoyl-estrone on the plasma lipoprotein profile and tissue lipase activities in order to determine the handling of circulating lipids by adipose tissue, liver and muscle of obese female rats.


METHODS
Lean (Fa/?) and obese (fa/fa) female Zucker rats treated for 10 days with a daily gavage of 0.2 ml sunflower oil containing 0 (controls) or 10 micromol/kg of oleoyl-estrone. After sacrifice, samples of tissues and plasma were taken.


METHODS
Plasma lipoprotein classes and composition; lipoprotein lipase and hepatic lipase activities in plasma, liver, skeletal muscle and periovaric and mesenteric white adipose tissue (WAT).


RESULTS
Oleoyl-estrone decreased plasma cholesterol (mainly in HDLs: 76%) of lean rats, but dramatically decreased all lipid classes in obese rats, in which chylomicra and VLDL lost most of their triacylglycerols (95 and 81%, respectively). Hepatic lipase activity decreased markedly with oleoyl-estrone in all groups, both in plasma (79% lean, 100% obese) and liver (62% in both groups). Lipoprotein lipase activity was largely unchanged by oleoyl-estrone in lean rats, but in the obese it decreased in WAT (82% in periovaric, and 49% in mesenteric), and increased in plasma (x4) and in skeletal muscle (x5); liver levels showed no change.


CONCLUSIONS
The shift observed in obese rats from a decrease in liver and WAT lipoprotein lipase and hepatic lipase activities to an increase in muscle lipoprotein lipase is coincident with the hypolipemic effect of oleoyl-estrone, especially in obese rats, and indicates that muscle is a key site for the disposal of endogenous fat mobilized due to oleoyl-estrone treatment.
Blay
M
M
Centre Especial de Recerca en Nutrició i Ciència dels Aliments, Facultat de Biologia, Universitat de Barcelona, Barcelona, Spain.
Peinado-Onsurbe
J
J
Grasa
M M
MM
Díaz-Silva
M
M
Fernandez-López
J A
JA
Remesar
X
X
Alemany
M
M
D000273:Adipose Tissue / Q000201:enzymology; D000818:Animals; D019440:Anti-Obesity Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D004970:Estrone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology*; D005260:Female; D008049:Lipase / Q000097:blood / Q000378:metabolism*; D008071:Lipoprotein Lipase / Q000097:blood / Q000378:metabolism; D008074:Lipoproteins / Q000097:blood*; D008099:Liver / Q000201:enzymology; D018482:Muscle, Skeletal / Q000201:enzymology; D009765:Obesity / Q000097:blood* / Q000201:enzymology*; D009829:Oleic Acids / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D011924:Rats, Zucker
D019440:Anti-Obesity Agents; D008076:Cholesterol, HDL; D008074:Lipoproteins; D009829:Oleic Acids; D004970:Estrone; C108709:oleoyl-estrone; D002784:Cholesterol; D008049:Lipase; D008071:Lipoprotein Lipase